|
Jun 19
|
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
|
|
Jun 18
|
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 17
|
Cathie Wood's Flagship Ark Innovation ETF Is Booming Again. Here's Why.
|
|
Jun 11
|
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
|
|
Jun 10
|
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
|
|
Jun 7
|
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 4
|
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
|
|
Jun 3
|
The Best Stocks to Invest $1,000 in Right Now
|
|
Jun 2
|
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
|
|
May 29
|
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
|
|
May 21
|
Crispr Therapeutics call volume above normal and directionally bullish
|
|
May 21
|
3 Top Genomics Stocks to Add to Your Portfolio in 2025
|
|
May 21
|
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug
|
|
May 20
|
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
|
|
May 20
|
5 Monster Stocks to Hold for the Next 10 Years
|
|
May 20
|
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
|
|
May 19
|
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
|
|
May 18
|
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
|